Search results
Showing 3301 to 3315 of 7680 results
Decision aid for Intrabeam radiotherapy system for adjuvant treatment of early breast cancer, TA501 c NICE 2018. All rights reserved. Subject to...
Study NICE and LSE's Executive MSc Healthcare Decision-Making
Study NICE and LSE's Executive MSc Healthcare Decision-Making
Technology appraisal and highly specialised technologies appeals
Technology appraisal and Highly specialised technologies appeals
Down to Rejected appeals Cancelled appeals Past appeals TA ID Appraisal short title Appeal hearing date TBC Afamelanotide for erythropoietic
This indicator covers the percentage of patients on the CKD register and with an albumin to creatinine ratio (ACR) of 70 mg/mmol or more, without diabetes, who are currently treated with an ARB or an ACE inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM247
NICE Advice is an advisory service for pharmaceutical and healthtech companies seeking to enter the NHS market, and supporting organisations who fund or generate evidence for health technologies.
Technology appraisal submission templates and supporting documents
On this page, you'll find all the templates and supporting documents you need to make a technology appraisals submission. These templates have been...
Urinary tract infection (lower). Patient decision aid on cystitis: taking an antibiotic
Cystitis: taking an antibiotic Information to help women who are not pregnant discuss the options with their healthcare professionals. Published...
Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Artificial intelligence (AI) and digital regulations service
NICE's leading role in designing a new service to support the development and adoption of AI and data-driven technologies in health and care.
The Commercial Liaison Team (CLT) works with companies who are considering a patient access scheme for their drug or treatment. Patient access schemes
Role and responsibilities of the National Institute of Health and Care Excellence
Advises NICE on the formulation of its guidance on the safety and efficacy of interventional procedures.
The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Show all sections
- Overview
- Introduction to real-world evidence in NICE decision making
- Conduct of quantitative real-world evidence studies
- Assessing data suitability
- Methods for real-world studies of comparative effects
- Appendix 1 - Data Suitability Assessment Tool (DataSAT)
- Appendix 2 - Reporting on methods used to minimise risk of bias
- Appendix 3 - Reporting information for selected analytical methods
We work with an independent indicator advisory committee (IAC) to develop indicators suitable for inclusion in the Quality and Outcomes Framework...